• Home
  • News
  • Fortune 500
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
    • Great Place to Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • FORTUNE 500
    • FORTUNE 500
    • FORTUNE SEA 500
    • Fortune 500 Europe
    • Fortune Global 500
    • Fortune China 500
    • Great Place to Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Banking
    • Investing
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics

Rebecca Torrence

  • SAN FRANCISCO, CA – JAN. 5: UCSF-Abbott Viral Diagnostics and Discovery Center lab director Dr. Charles Chiu demonstrates the process of extracting samples of COVID-19 for sequencing while working in his lab in San Francisco, Calif. Tuesday, January 5, 2021. Public health experts are increasingly concerned about the impact of highly contagious coronavirus variants. UCSF is running tests on the strains of the virus circulating in California to help identify new strains. (Jessica Christian/The San Francisco Chronicle via Getty Images)Health

    U.S. to invest $3.2 billion into COVID antiviral program

    By Riley Griffin, Rebecca Torrence, and others
    Rankings
    • 100 Best Companies
    • Fortune 500
    • Global 500
    • Fortune 500 Europe
    • Most Powerful Women
    • Future 50
    • World’s Most Admired Companies
    • See All Rankings
    Sections
    • Finance
    • Leadership
    • Success
    • Tech
    • Asia
    • Europe
    • Environment
    • Fortune Crypto
    • Health
    • Retail
    • Lifestyle
    • Politics
    • Newsletters
    • Magazine
    • Features
    • Commentary
    • MPW
    • CEO Initiative
    • Conferences
    • Personal Finance
    • Education
    Customer Support
    • Frequently Asked Questions
    • Customer Service Portal
    • Privacy Policy
    • Terms of Use
    • Single Issues for Purchase
    • International Print
    Commercial Services
    • Advertising
    • Fortune Brand Studio
    • Fortune Analytics
    • Fortune Conferences
    • Business Development
    About Us
    • About Us
    • Editorial Calendar
    • Press Center
    • Work at Fortune
    • Diversity and Inclusion
    • Terms and Conditions
    • Site Map

    © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.